Dasatinib

For research use only.

Catalog No.S1021 Synonyms: BMS-354825

266 publications

Dasatinib Chemical Structure

Molecular Weight(MW): 488.01

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 140 In stock
USD 147 In stock
USD 370 In stock
USD 597 In stock
USD 670 In stock
USD 817 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Dasatinib has been cited by 266 publications

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Description Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.
Targets
Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
0.6 nM 0.8 nM 37 nM 79 nM
In vitro

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M07ep210 NY\Hc3VJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXm3NkBp NFzXe5lFVVOR MYDJR|UxRTBwMECwNFch|ryP MnvLNVc6PTZyOEC=
K562 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\xfFczKGh? M4LPUWROW09? NEDIdmtKSzVyPUCuNFAyKM7:TR?= MlvsNVc6PTZyOEC=
M07e MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorvO|IhcA>? NIHs[pVFVVOR M17vcGlEPTB;MD6wNFEzKM7:TR?= NWXqSYZlOTd7NU[wPFA>
ALL3 Mk\jR5l1d3SxeHnjJGF{e2G7 M3HW[|AvOc7:TR?= MoC4O|IhcA>? MYDEUXNQ NFvKc4dKSzVyPUCuNFAxPCEQvF2= NWjPZmluOTl6OEm1OFA>
CML NILRfpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWSyNEBucW5? MYDEUXNQ NUni[48zUUN3ME2wMlAxOSEQvF2= MXKxPVIyQTBzNh?=
BA/F3 MoLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fqfVczKGh? MV3EUXNQ NUTVNmkzUUN3ME22MlU5QSEQvF2= M3W5blI{ODh6NkS0
BA/F3 MlPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH6zOpQ4OiCq NV\mZ2dMTE2VTx?= NFvleXBKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlGvSlMh[2WubIOg[ZhxemW|c3nu[{BD[3JvQXLsJG0{PTGWIH31eIFvfCC5aYToJGlEPTBib3[gNE4xODB6M988US=> NF6yeHAzOzB6OE[0OC=>
BA/F3 MlS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M16xeVczKGh? M{jLe2ROW09? MnPMTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy|IHX4dJJme3Orbnege4lt\CC2eYDlJGJkei2DYnyge4l1cCCLQ{WwJI9nKDBwMEC0Oe69VQ>? NFHHWpEzOzB6OE[0OC=>
BA/F3 M1PhdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYL4XVFNPzJiaB?= MVfEUXNQ M2Xwfmlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDtc5V{\SCEQT;GN{Bk\WyuczDlfJBz\XO|aX7nJGJkei2DYnygWFMyPUlibYX0ZY51KHerdHigTWM2OCCxZjCxMlcyPM7:TR?= MlfzNlMxQDh4NES=
BA/F3 NF\TdlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjE[Jk4OiCq NFywOFRFVVOR NGOy[nRKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCINEi2V{BufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFAxQc7:TR?= NVHoVXpUOjN|MEG3NFM>
BA/F3 NWrZc49uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjnZlVvPzJiaB?= NUewZYk6TE2VTx?= MXHJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBGOjV3SzDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECzNu69VQ>? MYiyN|MxOTdyMx?=
BA/F3 NUfI[|JLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHlPYs4OiCq NWfyflRoTE2VTx?= NH;wbJpKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCJMkWwSUBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFA2Oc7:TR?= MlvkNlM{ODF5MEO=
BA/F3 NV3HOZp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzwO|IhcA>? MX;EUXNQ MnjmTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhWTJ3MligcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwPO69VQ>? Mn;PNlM{ODF5MEO=
BA/F3 MoS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXT4TWdFPzJiaB?= MX3EUXNQ M{nIdmlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEV|NUnWJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFE{|ryP NIP1RpkzOzNyMUewNy=>
BA/F3 M13tfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUS3NkBp MUnEUXNQ MWXJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEKFUj3BRmwh[XO|ZYPz[YQh[XNiZ4Lve5RpKEmwaHnibZRqd25id3n0bEBKSzVyIH;mJFAvODBzOd88US=> NULJSplvOjN|MEG3NFM>
BA/F3 MlXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWK3NkBp NE\QUItFVVOR NFfnclRKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCC\MkWzTEBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFAzO87:TR?= MoXONlM{ODF5MEO=
BA/F3 MnPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLaWJI4OiCq NXnCPYRLTE2VTx?= MYXJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBVOzF3STDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDNwNt88US=> Mn7TNlM{ODF5MEO=
BA/F3 NV3qTZdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY[3NkBp NGDtcVNFVVOR NHXidVRKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCLbnjpZol1cW:wIIfpeIghUUN3MDDv[kAzNjYQvF2= MYCyN|MxOTdyMx?=
T cell NEC5fIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLlO|IhcA>? Ml[ySG1UVw>? NWfWXlNSUW6qaXLpeJMh[W62aTDDSFMuKGGwZDDhcpRqKEOGMkitbY5lfWOnZDDUJINmdGxicILvcIln\XKjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFPPxE1? MlfvNVcyPTR3MUK=
WiDr NFLKRWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13JcVczKGh? M3;1[2ROW09? NUHySVV7UUN3ME2wMlA2OiEQvF2= MlznNVU3OTV3MUK=
PC3 M1LLbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXIO|IhcA>? NF3hcGhFVVOR NULw[oMxUUN3ME2wMlAxQTRizszN NUnLc4hCOTV4MUW1NVI>
MDA-MB-231 M4LJNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX23NkBp Mk\ESG1UVw>? NH;xdXhKSzVyPUCuNFEzKM7:TR?= MlPxNVU3OTV3MUK=
Hs578T NGfkSG1EgXSxdH;4bYMhSXO|YYm= NFr0ZnM4OiCq NWDaOXlZTE2VTx?= MYHHTVUxRTBwMEOg{txO MVGyOFAyPTN{Nx?=
HMEC MX;DfZRwfG:6aXOgRZN{[Xl? MVK3NkBp MYXEUXNQ MojrS2k2OD1zLkig{txO M1GzN|I1ODF3M{K3
DU145 NEfpVYFEgXSxdH;4bYMhSXO|YYm= NV72SlU4PzJiaB?= MnvKSG1UVw>? MmfOS2k2OD1yLkG2JO69VQ>? MmXJNlQxOTV|Mke=
U251 NUC1VZRbS3m2b4TvfIlkKEG|c3H5 M3rze|czKGh? MXTEUXNQ M4qzOWdKPTB;Mj64NUDPxE1? NX:w[ZFqOjRyMUWzNlc>
NCI60 MUXDfZRwfG:6aXOgRZN{[Xl? MXK3NkBp NXvzUJlGTE2VTx?= M376UGdKPTB;NT63JO69VQ>? M2\1TlI1ODF3M{K3
MALME-3M NV3o[pVmS3m2b4TvfIlkKEG|c3H5 NXHGV4diPzJiaB?= NHftXZZFVVOR MXzHTVUxRTZwNkGg{txO MVqyOFAyPTN{Nx?=
KM12 MoL0R5l1d3SxeHnjJGF{e2G7 NX\ZUYluPzJiaB?= NV\Vd5BQTE2VTx?= NWrNS5luT0l3ME23MlQ1KM7:TR?= MVGyOFAyPTN{Nx?=
SW620 NVfJXZdOS3m2b4TvfIlkKEG|c3H5 NFXYdlY4OiCq NHfUVpdFVVOR MXjHTVUxRThwNEOg{txO NXPaemo4OjRyMUWzNlc>
RXF 393NL MnLpR5l1d3SxeHnjJGF{e2G7 NUjj[JprPCCmYYnz NGf5b3RFVVOR NXvMNHFXUUN3ME2wMlAzOTdizszN NHmwfYgzOzJ3M{C3OC=>
LXFA 983L Mn;vR5l1d3SxeHnjJGF{e2G7 MUW0JIRigXN? MofISG1UVw>? MUjJR|UxRTBwMEW2OUDPxE1? M{fYO|I{OjV|MEe0
PRXF DU145 MWXDfZRwfG:6aXOgRZN{[Xl? MknOOEBl[Xm| NX31PGtKTE2VTx?= MV\JR|UxRTBwME[yN{DPxE1? NVO1d3JKOjN{NUOwO|Q>
PAXF 1657L MoryR5l1d3SxeHnjJGF{e2G7 M1j5clQh\GG7cx?= MnLjSG1UVw>? MV;JR|UxRTBwMUKxJO69VQ>? NIrndpMzOzJ3M{C3OC=>
CXF 1103L M2DFSWN6fG:2b4jpZ{BCe3OjeR?= M{Dkc|Qh\GG7cx?= NX63WYVLTE2VTx?= NUXUfFlOUUN3ME20MlM3KM7:TR?= MYiyN|I2OzB5NB?=
GXF251L NIrvdVdEgXSxdH;4bYMhSXO|YYm= NUflXI9uPCCmYYnz M4TqXWROW09? MnfSTWM2OD1{LkK1JO69VQ>? NXnXNnNTOjN{NUOwO|Q>
NCI-H23 NGLudoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3sO|IhcA>? NXjKXFJoTE2VTx?= M1;GUWlEPTB;Mj6yO{DPxE1? M{\zVFI{PTJzMEKw
HCT116 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfMO|IhcA>? MXLEUXNQ M4HaTmlEPTB;Mj6zJO69VQ>? NVHSUnJjOjN3MkGwNlA>
MCF7 NEnZbpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrTO|IhcA>? NGO2TYVFVVOR MY\JR|UxRTJwNUeg{txO NVXCRWxkOjN3MkGwNlA>
NCI-H460 NXzWNHNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVz2Z3dKPzJiaB?= NIfMSnJFVVOR NG\xNFZKSzVyPUiuPVkh|ryP MWCyN|UzOTB{MB?=
DLD1 MoDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXrO|IhcA>? NYnxWo1JTE2VTx?= NV6wNGt5UUN3ME20MlYh|ryP M2nHUVI{PTZ5OU[w
NCI-H661 MlLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjib|I4PzJiaB?= NHPYdZlFVVOR NFnQXJNKSzVyPUeuPEDPxE1? Mmi1NlM2Pjd7NkC=
A549 NYDITYlMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYW3NkBp NES3R2pFVVOR NXHa[o02UUN3ME24MlIh|ryP MVmyN|U3Pzl4MB?=
U937 NYTyfWxkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILWcnY4OiCq Ml3zSG1UVw>? NFXDWW9KSzVyPUGyMlIh|ryP M4HhUVI{PTZ5OU[w
HEK293 M33ZXGZ2dmO2aX;uJGF{e2G7 NYXrc2VTOTEEoN88US=> NHLPXZFFVVOR MV;JcoR2[2W|IHLpcoRqdmdiYX\mbY5qfHlidH:gbJVu[W5iZoXscE1t\W6pdHigTIl{NXSjZ3fl[EBOgXRzIHvpcoF{\SCneIDy[ZN{\WRiaX6gTGVMOjl|IHPlcIx{KHerdHigTWM2OCCxZjCwMlA3O87:TR?= MoSxNlI4PzB4MUC=
HUVEC NE\MWVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7vW|g6OC5zNdMg{txO M2TVXlczKGh? MonRSG1UVw>? MXrJcoR2[2W|IHHueIlidmerb3flcolkKGGldHn2bZR6KGmwIFjVWmVEKGOxLXP1cJR2emWmIIfpeIghfmG|Y4XsZZIhe22xb4ToJI12e2OuZTDj[YxteyCjc4Pld5Nm\CCjczDJcohq[mm2aX;uJI9nKGOnbHyg[5Jwf3SqIHH0JFAvOTVidV2= M3f0bVIzQDV|OUmz
HUVEC MkXuSpVv[3Srb36gRZN{[Xl? MVyxOeKh|ryP M3n5TFczKGh? MlnrSG1UVw>? NFzLco5KdmS3Y3XzJIFvfGmjbnfpc4dmdmmlIHHjeIl3cXS7IHnuJGhWXkWFIHPvMYN2dHS3cnXkJJdqfGhidnHzZ5Vt[XJic33vc5RpKG23c3Ps[UBk\WyuczDhd5Nme3OnZDDhd{BKdmirYnn0bY9vKG:oIH7leJdwemtiZn;ycYF1cW:wIHH0JFEvQCC2bzCxOUB2VQ>? M4TpSFIzQDV|OUmz
Plasmodium falciparum MWrGeY5kfGmxbjDBd5NigQ>? NFfSdogyOMLizszN Mnz1NVUhdWmw M2rOZmROW09? NFz2NHJKdmirYnn0d{BRdGG|bX;kbZVuKG[jbHPpdIFzfW1icILvcIln\XKjdHnvckBjgSCrbnjpZol1cW6pIITo[UBHfW6ldHnvckBw\iCSZlPEVGsyKHC{b4TlbY4hf2m2aDDJR|UxKG:oIEGuNVfPxE1? MXuyOFU2ODN|MB?=
PC3 Ml\oSpVv[3Srb36gRZN{[Xl? NVPQOmhnOC5zIN88US=> NVj6e|V4PSCq M1XqUGROW09? M{T1dGlvcGmkaYTzJIh2dWGwIGDDN{Bk\WyuIHHkbIV{cW:wIHH0JFExOCCwTR?= M4f1clE6PDZ{OUe1
DU145 M3X3[2Z2dmO2aX;uJGF{e2G7 Mly0NE4yKM7:TR?= MXy1JIg> M4q2eWROW09? M1jwTmlvcGmkaYTzJIh2dWGwIFTVNVQ2KGOnbHygZYRp\XOrb36gZZQhOTByIH7N NXLaZnpvOTl2NkK5O|U>
PC3 MoL4T4lv[XOnIFHzd4F6 NWXIcI5KOC5zIN88US=> NF74[mo2KGh? Mle0SG1UVw>? M2TkUWlvcGmkaYTzJINUemNiaX6gbJVu[W5iUFOzJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBUemNiWUSxOkBt\X[nbDDheEAyODBibl2= Mo\NNVk1PjJ7N{W=
DU145 NXT3O402U2mwYYPlJGF{e2G7 NFzLdmkxNjFizszN MVG1JIg> M3LSW2ROW09? M121WWlvcGmkaYTzJINUemNiaX6gbJVu[W5iRGWxOFUh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKFO{YzDZOFE3KGyndnXsJIF1KDFyMDDuUS=> NGHkSZIyQTR4Mkm3OS=>
PC3 NFTtOY5McW6jc3WgRZN{[Xl? NFnsV|cxNjFizszN MnzWOUBp MmHBSG1UVw>? M2HCSmlvcGmkaYTzJINUemNiaX6gbJVu[W5iUFOzJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBHSUtiWUW3Ok9[PTd5IHzleoVtKGG2IEGwNEBvVQ>? NHn2V2IyQTR4Mkm3OS=>
DU145 NF:3d2ZMcW6jc3WgRZN{[Xl? NFO2cXUxNjFizszN M1nG[|UhcA>? MX3EUXNQ M2\QeGlvcGmkaYTzJINUemNiaX6gbJVu[W5iRGWxOFUh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKE[DSzDZOVc3N1l3N{egcIV3\WxiYYSgNVAxKG6P NIHlOYIyQTR4Mkm3OS=>
Huh7 M4q2WGFvfGm4aYLhcEBCe3OjeR?= NYjpZ5RUOi53IN88US=> MlzzOEBl[Xm| M1u1WmROW09? NYX0PYd5UW6qaXLpeJMhfmm{YXygd5Bz\WGmIHnuJGRmdme3ZTD2bZJ2ey2rbn\lZ5Rm\CCqdX3hckBJfWh5IHPlcIx{KGG|c3Xzd4VlKGG|IHHjZ5VufWyjdHnvckBw\iC4aYLhcEBmdn[nbH;w[UBxem:2ZXnuJJdqfGirbjDw[ZJqdnWlbHXhdkBz\Werb36gZZQhOi53IIXN MWKxO|M3ODZ5Nh?=
C6/36 NGnybVVCdnSrdnnyZYwhSXO|YYm= M1HZWVIvPSEQvF2= NIXUU3c1KGSjeYO= Mn;XSG1UVw>? Mk\lTY5pcWKrdIOgeolz[Wxic4Dy[YFlKGmwIFTlcod2\SC4aYL1d{1qdm[nY4Tl[EBie2mjbjD0bYdmeiCvb4PxeYl1dyCFNj:zOkBk\WyuczDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25ib3[geolz[WxiZX72[YxweGVicILveIVqdiC5aYTobY4heGW{aX71Z4xm[XJicnXnbY9vKGG2IEKuOUB2VQ>? M4\kZlE4OzZyNke2
U937 MW\GeY5kfGmxbjDBd5NigQ>? MYKxJO69VQ>? NEnYdnUyKGh? M4DYUWROW09? M3O2b3Jm\HWlZYOgZoF{[WxiVF7GZYxxcGFicnXs[YF{\SCrbjDoeY1idiCXOUO3JINmdGy| M4fZOFE4Pjh2MEm5
U937 NHnNRWdHfW6ldHnvckBCe3OjeR?= NX2xbHdVOSEQvF2= NU\FPGk5OSCq NY\OcIZUTE2VTx?= M{fYbnJm\HWlZYOgUHBUNWmwZIXj[YQhXE6IYXzwbIEhemWuZXHz[UBqdiCqdX3hckBWQTN5IHPlcIx{ NXryVW5QOTd4OESwPVk>
murine mast cell M2XUdmZ2dmO2aX;uJGF{e2G7 NF\zRZQyKM7:TR?= Mn;vNlQhcA>? MYXEUXNQ MmrvTY5pcWKrdIOgZY51cWenbj3pcoR2[2WmIFnMOkB{\WO{ZYTpc44hcW5iSXfFJJBzcW2nZDDtc5V{\SCvYYP0JINmdGy|IHH0JFEhfU1? M1LxOFE4Pjh2MEm5
BV-173 M4TaNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfl[ndwUUN3ME2wMlAxODByMEGwPUDPxE1? MoHsV2FPT0WU
K-562 NUfNeYUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7zTWM2OD1yLkCwNFAxODJ4NjFOwG0> MU\TRW5ITVJ?
BL-70 M{L0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV20W4tZUUN3ME2wMlAxODByMEiyNkDPxE1? NX23[ItIW0GQR1XS
EM-2 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjFfJBKSzVyPUCuNFAxODBzMEig{txO NV3CN4J3W0GQR1XS
LAMA-84 M2DQUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDmdVJKSzVyPUCuNFAxODB|MkGg{txO MYTTRW5ITVJ?
MEG-01 M2DMcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vnO2lEPTB;MD6wNFAxODl6IN88US=> NVqxVnlkW0GQR1XS
EoL-1-cell NULUNoJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlO1TWM2OD1yLkCwNFAyOzFizszN M{XtXnNCVkeHUh?=
CTV-1 NVzEUFBXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXruUnJ7UUN3ME2wMlAxODB2MESg{txO MmW1V2FPT0WU
TE-15 NH:yfppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjZTWM2OD1yLkCwOVg6KM7:TR?= M3XD[XNCVkeHUh?=
NOS-1 M{nPT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Lm[GlEPTB;MD6wNFYyOyEQvF2= NXLxU49WW0GQR1XS
D-336MG M1jkbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTaTWM2OD1yLkCwOlMh|ryP Ml;lV2FPT0WU
LB1047-RCC NGLWUpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7nNXlJUUN3ME2wMlAxQTh7IN88US=> NWn0RmRRW0GQR1XS
LB996-RCC M4nUZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWniSJkzUUN3ME2wMlAxQTlzIN88US=> MVXTRW5ITVJ?
SW982 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTBwMEGxNVUh|ryP Mn;EV2FPT0WU
TK10 NUm4R2lbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3LflhKSzVyPUCuNFEyPzRizszN NYO1O3pEW0GQR1XS
A704 M2XyOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPON4NKSzVyPUCuNFE1QTFizszN NWC2V|AzW0GQR1XS
TE-8 Mn;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUO4XGhxUUN3ME2wMlAyPTd4IN88US=> NEPJfYtUSU6JRWK=
DOHH-2 M{HJVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDMZWZKSzVyPUCuNFE4OTlizszN MUDTRW5ITVJ?
HOP-62 M2DHb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkj6TWM2OD1yLkCxPFM1KM7:TR?= NFPpfoxUSU6JRWK=
TE-12 NHW2fW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfWfXhKSzVyPUCuNFE5PjFizszN NIi0bHFUSU6JRWK=
KGN MmfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPYWZhZUUN3ME2wMlAyQTR{IN88US=> MmrSV2FPT0WU
NCI-H1648 MmHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVm1T3U5UUN3ME2wMlAzODFzIN88US=> NV7QT5ozW0GQR1XS
OS-RC-2 NFvubFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFr2cmtKSzVyPUCuNFIxOyEQvF2= NEK5WXpUSU6JRWK=
GB-1 M4r2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnH6TWM2OD1yLkCyNVU4KM7:TR?= MXTTRW5ITVJ?
RXF393 NHLncohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nsWGlEPTB;MD6wNlM2PyEQvF2= NEe0SGtUSU6JRWK=
LC-2-ad MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjv[HJlUUN3ME2wMlAzPTh4IN88US=> M3XVNXNCVkeHUh?=
KS-1 NULNfHlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37JNGlEPTB;MD6wNlc{KM7:TR?= MmTYV2FPT0WU
ETK-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PEfGlEPTB;MD6wNlg{OiEQvF2= MVfTRW5ITVJ?
SW954 NHSwfphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTBwMEK5Nlch|ryP MYHTRW5ITVJ?
Becker M1fUSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYS4c2ZUUUN3ME2wMlA{ODB|IN88US=> NXzvWmxPW0GQR1XS
MZ1-PC M{C2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zDNmlEPTB;MD6wN|EyQSEQvF2= M4f3dnNCVkeHUh?=
ES6 NWr2e4tOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfXTWM2OD1yLkCzNVk{KM7:TR?= MUXTRW5ITVJ?
KURAMOCHI M1LWOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\HNo5KSzVyPUCuNFM1QDdizszN MYDTRW5ITVJ?
CGTH-W-1 NWfB[ot2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTBwMEO1OFgh|ryP MX7TRW5ITVJ?
VA-ES-BJ MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofiTWM2OD1yLkCzPVAzKM7:TR?= M{C4RnNCVkeHUh?=
LXF-289 NXvxR2lUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmK2TWM2OD1yLkCzPVU3KM7:TR?= MoTMV2FPT0WU
MPP-89 M1\ZTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLNTWM2OD1yLkC0NFQ6KM7:TR?= M{T0[nNCVkeHUh?=
SW872 M2HJWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknBTWM2OD1yLkC0NVYyKM7:TR?= MYfTRW5ITVJ?
SNB75 NYHaSZlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTBwMES0N|Uh|ryP NXm4dlhJW0GQR1XS
PSN1 MnHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEG2PYlKSzVyPUCuNFQ1PzRizszN MUXTRW5ITVJ?
LB831-BLC M3\4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DXcWlEPTB;MD6wOFYxQSEQvF2= NFPGNHlUSU6JRWK=
MFH-ino MnezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7KO3NSUUN3ME2wMlA1PzJ2IN88US=> NHrCb4NUSU6JRWK=
TGBC24TKB NXjFNmRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPsZ4xJUUN3ME2wMlA1PzZzIN88US=> NIrQU|RUSU6JRWK=
A388 Mn\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXHbmRKSzVyPUCuNFUxQTVizszN MVnTRW5ITVJ?
BB30-HNC Mkf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrRZXhKSzVyPUCuNFU1OzdizszN M2H0UnNCVkeHUh?=
GI-ME-N NUOwSWlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXLTWM2OD1yLkC2NVE5KM7:TR?= MmjMV2FPT0WU
TGBC1TKB MmXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDETWM2OD1yLkC2NVY1KM7:TR?= NGLVO2dUSU6JRWK=
TE-10 NUDEdoVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPodm9KSzVyPUCuNFY{PTdizszN M3iye3NCVkeHUh?=
A498 NVvsfG1IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\jSHVKSzVyPUCuNFczQDRizszN MmjXV2FPT0WU
TE-11 M3q1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUL3UnhkUUN3ME2wMlA4QDV6IN88US=> MkixV2FPT0WU
BB65-RCC NX3XOXpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTBwMEiyNlch|ryP M33vTnNCVkeHUh?=
C2BBe1 MoLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2O0cWlEPTB;MD6wPFMxQCEQvF2= M1TT[3NCVkeHUh?=
NCI-H747 NX[1WpBuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvRTWM2OD1yLkC4N|YzKM7:TR?= M{L2S3NCVkeHUh?=
IST-MES1 M4Pze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwMEi1OVIh|ryP M1jwZXNCVkeHUh?=
KALS-1 MmPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLHTWM2OD1yLkC5OFkh|ryP Ml\iV2FPT0WU
GCIY NHfud2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvhTWM2OD1yLkC5OlU3KM7:TR?= M37tcHNCVkeHUh?=
RL95-2 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NET1WppKSzVyPUCuNVA{QCEQvF2= NXK0N5BNW0GQR1XS
TE-1 NX\6[ZI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETJUWRKSzVyPUCuNVA2PCEQvF2= NWTiSmxoW0GQR1XS
NCI-H1355 M1z3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTPbZdVUUN3ME2wMlEyODJ6IN88US=> MW\TRW5ITVJ?
SW962 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTBwMUGyPVIh|ryP MlvZV2FPT0WU
KLE MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTjcnpwUUN3ME2wMlEyOzF5IN88US=> NEHwXI1USU6JRWK=
MC116 NHftN4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{D0UmlEPTB;MD6xNVQyKM7:TR?= M{WwTnNCVkeHUh?=
NMC-G1 NXXxWIxCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XXPWlEPTB;MD6xNVYxPiEQvF2= MWnTRW5ITVJ?
KU812 NXPaUIgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTMTWM2OD1yLkGxPFg{KM7:TR?= NIHoR25USU6JRWK=
COLO-829 NILqOGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjz[FRKSzVyPUCuNVIzOTNizszN MXHTRW5ITVJ?
NTERA-S-cl-D1 M3jLb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTBwMUKyPFMh|ryP NYmyfZNvW0GQR1XS
IST-MEL1 NWH1XYR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTBwMUO0OUDPxE1? MVTTRW5ITVJ?
MLMA NHTkPINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTOeW5zUUN3ME2wMlE1ODN{IN88US=> NE\tWGpUSU6JRWK=
LS-123 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlizTWM2OD1yLkG0NFY1KM7:TR?= NX;zdFZpW0GQR1XS
LB2518-MEL NEmxcJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1viRmlEPTB;MD6xOFE3OiEQvF2= M1;sVHNCVkeHUh?=
NB69 MnO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\ZUGVRUUN3ME2wMlE1PDN4IN88US=> Mn;OV2FPT0WU
8-MG-BA NVexTIZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnNW3VUUUN3ME2wMlE2PDV6IN88US=> NWfZcJhqW0GQR1XS
K5 NU\IXJZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;JS|ZKSzVyPUCuNVY1QDlizszN NGjrbnNUSU6JRWK=
KINGS-1 M1ex[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfsUpp4UUN3ME2wMlE3PjZ4IN88US=> MlK4V2FPT0WU
SF268 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fJTWlEPTB;MD6xO|QxPCEQvF2= M{PlWXNCVkeHUh?=
PF-382 NIr2eVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{KyOWlEPTB;MD6xO|Y4QCEQvF2= MlvSV2FPT0WU
SH-4 M3XDbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHibmhQUUN3ME2wMlE5PDF|IN88US=> MYDTRW5ITVJ?
NALM-6 MnzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTBwMUmyPVUh|ryP MnjnV2FPT0WU
CP66-MEL MlTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLZTWM2OD1yLkG5OVMyKM7:TR?= NF76ZWJUSU6JRWK=
697 Mk\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvXTWM2OD1yLkG5PVg4KM7:TR?= MoLUV2FPT0WU
CP67-MEL NYTwbIhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHL5NolKSzVyPUCuNlA1QDhizszN MV;TRW5ITVJ?
DSH1 NFHDcZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjtUIdKSzVyPUCuNlQxODFizszN NUC2WmREW0GQR1XS
HCE-4 MmjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17HRmlEPTB;MD6yOlQ{QSEQvF2= NHn5Vm5USU6JRWK=
MZ2-MEL MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\o[HV5UUN3ME2wMlI5PTN5IN88US=> NIHsd49USU6JRWK=
BL-41 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPZN2tKSzVyPUCuNlkyOjNizszN M1fHNXNCVkeHUh?=
HUTU-80 Mk\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PEc2lEPTB;MD6zNVQzKM7:TR?= NUPw[nNxW0GQR1XS
LOXIMVI NXi4UJdMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fWe2lEPTB;MD6zNVUxOyEQvF2= MUnTRW5ITVJ?
no-10 MnLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnTcXVmUUN3ME2wMlMyQTNzIN88US=> MVTTRW5ITVJ?
KARPAS-422 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFr1U4tKSzVyPUCuN|M6QTdizszN Mnr6V2FPT0WU
SW684 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXNTWM2OD1yLkO0PVgh|ryP NVnTeVM4W0GQR1XS
SF126 M3fCZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXH5PHpxUUN3ME2wMlM2PDFizszN NUnsUIlMW0GQR1XS
D-263MG NX3rfXRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfTNFRPUUN3ME2wMlM3OjJ2IN88US=> MnHXV2FPT0WU
OVCAR-4 NIPiZVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrSNXlOUUN3ME2wMlM4PDN|IN88US=> MXvTRW5ITVJ?
BB49-HNC NHn3bnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LIS2lEPTB;MD6zPFU6QSEQvF2= MlqwV2FPT0WU
ONS-76 M3XyRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HTNWlEPTB;MD60Nlk2OSEQvF2= MljBV2FPT0WU
MZ7-mel M3;y[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjRZ41KSzVyPUCuOFc6OTFizszN NGW3cGFUSU6JRWK=
RCC10RGB NVv3NIVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjZWW54UUN3ME2wMlQ6OTFizszN MYnTRW5ITVJ?
BOKU MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTBwNEmxN|Mh|ryP MmnJV2FPT0WU
no-11 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrSe41KSzVyPUCuOVAzOjhizszN Mn2wV2FPT0WU
IST-SL2 MonNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFja[XJKSzVyPUCuOVA{ODJizszN M4LBOHNCVkeHUh?=
RKO MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXXbYxKSzVyPUCuOVI6PjZizszN NIPLOGRUSU6JRWK=
HT-144 NIXrXXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\aT5RZUUN3ME2wMlU{PjB7IN88US=> MV;TRW5ITVJ?
NCI-H446 MkL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\R[3VkUUN3ME2wMlYzPzZizszN MWLTRW5ITVJ?
QIMR-WIL MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\1XHNnUUN3ME2wMlcxPjJ7IN88US=> MmjJV2FPT0WU
MHH-PREB-1 MnG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfnfpdKSzVyPUCuO|Q1PjlizszN MYXTRW5ITVJ?
EW-16 NGnm[WtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DVO2lEPTB;MD63OlE4QCEQvF2= NF7NUlFUSU6JRWK=
EW-24 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTBwN{ixOlUh|ryP NYTL[XNLW0GQR1XS
LB373-MEL-D MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTBwOEK1NFgh|ryP MWXTRW5ITVJ?
TE-9 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwOEe1N|Ih|ryP NUKwZWs1W0GQR1XS
A3-KAW MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTBwOUi0OVIh|ryP Mlj0V2FPT0WU
A101D NH\CcolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\hRWpiUUN3ME2xMlA{ODR|IN88US=> MlvjV2FPT0WU
OCUB-M M1XoO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\yc295UUN3ME2xMlA1PDF{IN88US=> NHW3U3FUSU6JRWK=
ES4 NVr1NII{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTFwMEWxOFUh|ryP NH3yN2hUSU6JRWK=
TE-6 MmrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTFwMkGyNlYh|ryP NET0SHZUSU6JRWK=
D-502MG NFu0TXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1z2UmlEPTB;MT6yN|M4PiEQvF2= MoXJV2FPT0WU
KNS-42 M2rr[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTFwMkS0NVIh|ryP NUDa[mtXW0GQR1XS
SNU-C2B NG\3ZWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlm3TWM2OD1zLkOwOVg6KM7:TR?= Mm\GV2FPT0WU
NCI-H1838 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLUTYxoUUN3ME2xMlMxPzN|IN88US=> NH;CS3NUSU6JRWK=
NKM-1 NH7Tc5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rINGlEPTB;MT6zNFg2QSEQvF2= M3PvTXNCVkeHUh?=
GI-1 NW[2bYM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LvS2lEPTB;MT6zOlIzKM7:TR?= NE\F[XFUSU6JRWK=
NB5 MmXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7nTWM2OD1zLkO5PFI4KM7:TR?= MWjTRW5ITVJ?
CAS-1 MmnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTFwNEC5PVIh|ryP MkLkV2FPT0WU
HCE-T M1LrWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLDW4NKSzVyPUGuOVY4OTRizszN NF74fmpUSU6JRWK=
SBC-1 M2[0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHFeWNKSzVyPUGuOVc6QDRizszN M1rpU3NCVkeHUh?=
JiyoyeP-2003 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTFwN{O0OlYh|ryP NIjLXIFUSU6JRWK=
TE-5 NF\PeVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDEU|JXUUN3ME2xMlc6OTN7IN88US=> NVXlV4pzW0GQR1XS
CAN NUjBTlA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TuVmlEPTB;MT64NlI2OiEQvF2= NVnSXHhQW0GQR1XS
SK-UT-1 MkLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TXeWlEPTB;Mj6xOlY6OyEQvF2= NIqzXXZUSU6JRWK=
JVM-2 NX6wbY1RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vGTGlEPTB;Mj6zOlI5PCEQvF2= MUTTRW5ITVJ?
LB771-HNC M1f5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\nO5RKSzVyPUKuOVc2PTFizszN Ml\RV2FPT0WU
NCCIT NWHtWo9vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjaeFVKSzVyPUKuPFY3OTZizszN M1\GNnNCVkeHUh?=
NCI-H2126 Mlv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkW2TWM2OD1{Lki3OVUzKM7:TR?= NGLrOmpUSU6JRWK=
Calu-6 NVPGR3JJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnX2TWM2OD1|LkC1O|QyKM7:TR?= NFjRb|JUSU6JRWK=
SK-LMS-1 M{fWSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTNwMUG4PFYh|ryP M1G1W3NCVkeHUh?=
ARH-77 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTBTWM2OD1|LkS2PVE2KM7:TR?= MoXSV2FPT0WU
NB17 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTsfnVTUUN3ME2zMlY{QDR5IN88US=> MX;TRW5ITVJ?
A253 NELuZXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Pse2lEPTB;Mz63N|I1PiEQvF2= NF3ONZBUSU6JRWK=
OPM-2 M2Hvfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvqTWM2OD12LkK3Olg2KM7:TR?= MX;TRW5ITVJ?
MV-4-11 NYfR[XdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nPVWlEPTB;ND6zOlQ2PCEQvF2= NUH3fXI4W0GQR1XS
SR MlfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF32c4tKSzVyPUSuOFk6PTRizszN M2XHTnNCVkeHUh?=
KG-1 NEXEXWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTRwNkC4OFUh|ryP M2KybnNCVkeHUh?=
OCI-AML2 M2j1dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojETWM2OD13Lki2NVU1KM7:TR?= M2PCbXNCVkeHUh?=
D-247MG NXGwN291T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHr6TY9KSzVyPU[uNVI2OTlizszN M2LLTnNCVkeHUh?=
DJM-1 M{Dnc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PDU2lEPTB;Nj60PFU2QCEQvF2= NUXKZ5o2W0GQR1XS
RPMI-6666 M2C4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnCU2tzUUN3ME23MlI4ODZ5IN88US=> MVvTRW5ITVJ?
KARPAS-45 M3H1VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4D2eGlEPTB;Nz61NVY4OSEQvF2= M13oUnNCVkeHUh?=
LP-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTdwNUS3PFIh|ryP M2T6VHNCVkeHUh?=
RS4-11 Mn35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTdwNkW3PFch|ryP Ml;TV2FPT0WU
DU-4475 NG\nVI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;aNINKSzVyPUiuNlE3PTJizszN M1XofXNCVkeHUh?=
MONO-MAC-6 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDxdlg4UUN3ME24MlI4ODZ4IN88US=> MVnTRW5ITVJ?
NCI-SNU-16 M2fmdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTJN3VkUUN3ME24MlU3OTJ6IN88US=> M4DjbXNCVkeHUh?=
SJSA-1 MlPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHn1VHNKSzVyPUiuO|I5ODVizszN NYfRclJvW0GQR1XS
MMAC-SF NIPIcmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvveZpKSzVyPUiuO|k{ODdizszN Mk[5V2FPT0WU
SK-NEP-1 M3;W[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETw[G5KSzVyPUiuPFkyPTVizszN M{ezVXNCVkeHUh?=
J-RT3-T3-5 NFnPTo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHnTXR[UUN3ME24Mlk3PTJ7IN88US=> NXzae|B{W0GQR1XS
SKM-1 NV3PWIJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTlwMEG3N|Qh|ryP MVPTRW5ITVJ?
LB2241-RCC NEiwSYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2m3S2lEPTB;OT6wNlAyOiEQvF2= NIHhelJUSU6JRWK=
SIG-M5 M1Xo[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfVPZZwUUN3ME25MlAzPDl|IN88US=> NYrtcphYW0GQR1XS
EVSA-T NGrXWJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTlwMke3PVMh|ryP M2LodHNCVkeHUh?=
GT3TKB NGraeotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETLXY1KSzVyPUmuN|U2PDZizszN Mn;rV2FPT0WU
NB6 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXwfmtUUUN3ME25MlkzOjV7IN88US=> MVfTRW5ITVJ?
EHEB M2\qPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPvTWM2OD1zMD6wOlU3KM7:TR?= M2e4U3NCVkeHUh?=
HEL NUj4RZhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHtcldKSzVyPUGwMlQ4PzZizszN MV\TRW5ITVJ?
ALL-PO MmC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTFyLke5N|gh|ryP NWrWemFzW0GQR1XS
TGW M3LKc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkj0TWM2OD1zMT6yPFI5KM7:TR?= NYDDXo0xW0GQR1XS
BC-3 NFjJbGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInwfJFKSzVyPUGyMlEyOzhizszN NWnSdpRrW0GQR1XS
IA-LM MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\SUVVKSzVyPUGyMlQ1PDVizszN NHfZO4JUSU6JRWK=
UACC-257 MoDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTF{LkmxPVgh|ryP MoXPV2FPT0WU
KP-N-YS NHz4R45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTF{LkmyPFMh|ryP MUfTRW5ITVJ?
Raji M{fIeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLRTWM2OD1zMz63OFk4KM7:TR?= MlraV2FPT0WU
SF539 NGDxT|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWO0VYM4UUN3ME2xN{45PTV5IN88US=> NE\xTXpUSU6JRWK=
DMS-153 M{P0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3voe2lEPTB;MUSuNFAzQCEQvF2= NUnLbGJXW0GQR1XS
L-540 NVvBVlZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHu4NJVKSzVyPUG1MlA3PzJizszN MXfTRW5ITVJ?
MN-60 NVHmWG13T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlSxTWM2OD1zNT6xPVc6KM7:TR?= MUXTRW5ITVJ?
RPMI-8866 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTF5LkS0OVQh|ryP Mlu5V2FPT0WU
NCI-H510A MkjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnRTWM2OD1zOT6zPVc{KM7:TR?= M4XvdHNCVkeHUh?=
NB13 M1vEXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrFZopKSzVyPUG5MlQ5PzdizszN NGrndWJUSU6JRWK=
HAL-01 Mmi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XqS2lEPTB;MUmuO|U1OyEQvF2= NXPYfJhlW0GQR1XS
NCI-H720 M1fGPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2[wd2lEPTB;MkCuNlc{OyEQvF2= NH;TS|RUSU6JRWK=
REH M4jhUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jMSWlEPTB;MkCuOlM2PyEQvF2= MV7TRW5ITVJ?
KNS-81-FD NVrHV|BVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPVfVBKSzVyPUKzMlE1PiEQvF2= M3j5U3NCVkeHUh?=
HC-1 NVHVXmZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4P1[mlEPTB;MkSuOVU2OSEQvF2= Mmj6V2FPT0WU
NCI-H2141 NH60RZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITBfGRKSzVyPUK0Mlc4PTRizszN MlPiV2FPT0WU
MOLT-4 NWrVXlMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfqTG9TUUN3ME2yOk43PzV|IN88US=> NYDTW5VsW0GQR1XS
OMC-1 MnP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHveW9KSzVyPUK3MlE1OjJizszN M1izSnNCVkeHUh?=
LC-1F M371dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;oTWM2OD1{Nz6zNlQ2KM7:TR?= NG\QVGxUSU6JRWK=
NCI-H1304 M4fuVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTJ6LkG2Nlgh|ryP NXjzR4RrW0GQR1XS
BC-1 MlvBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\oRmlEPTB;MkiuOlUyKM7:TR?= MYfTRW5ITVJ?
NCI-H64 NF7nZXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFr0dHRKSzVyPUK5MlYzPTNizszN NGXBenNUSU6JRWK=
MOLT-16 NGXSVmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTJ7Lk[yPVIh|ryP M1PQenNCVkeHUh?=
U-87-MG NXPwT2hbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHWfZpKSzVyPUOwMlc3PiEQvF2= MXnTRW5ITVJ?
GAK Mo\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfMTWM2OD1|MT6yOlg3KM7:TR?= MlrnV2FPT0WU
ES8 MoTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\OR2FKSzVyPUOyMlEzPTJizszN M3[1PXNCVkeHUh?=
HCC1599 Mnu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1i3NWlEPTB;M{KuN|MzPSEQvF2= MoX0V2FPT0WU
EB-3 NUfSUopRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTN2LkOxNVch|ryP M1\qN3NCVkeHUh?=
HCC1187 MkHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTN3LkiwOVIh|ryP NVG4RXdsW0GQR1XS
SK-PN-DW NVTXbpNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHz1fY1KSzVyPUO2MlE6PDNizszN Moj4V2FPT0WU
JVM-3 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3HbXBvUUN3ME2zO{4zOzN6IN88US=> M370[3NCVkeHUh?=
HCC2157 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHT2VGFKSzVyPUO3Mlk6PDZizszN M4D1NnNCVkeHUh?=
A4-Fuk MnfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUm4fHlDUUN3ME2zPE4yODB7IN88US=> M4jmSHNCVkeHUh?=
COR-L279 M3P5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLaUI5YUUN3ME20NE4zQDVzIN88US=> NFzmXGhUSU6JRWK=
DEL M2r5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFewTIxKSzVyPUSxMlkxQDZizszN Ml\oV2FPT0WU
NCI-H1395 NWC3RXZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPTdZpKSzVyPUSyMlAyPjNizszN MlHmV2FPT0WU
MHH-NB-11 NWHOfI83T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7ucJdzUUN3ME20N{4xQDF6IN88US=> NWWwPYlUW0GQR1XS
NCI-H2107 NYXZN3dDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnP6TWM2OD12Mz60PFQ3KM7:TR?= NW\RW2N{W0GQR1XS
NEC8 NH3SfmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TieWlEPTB;NESuN|M3KM7:TR?= M324[XNCVkeHUh?=
COLO-684 NWjzTIg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjkUmNKSzVyPUS2MlIzPThizszN NEHpbFBUSU6JRWK=
LS-411N NXL6S5Z2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTR6LkS3OFgh|ryP NEnsfYhUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
phospho-c-Abl(Tyr245) / phospho-c-Src(Tyr416); 

PubMed: 23049975     


Protein levels of phosphorylated c-Abl (Tyr245), c-Abl, phosphorylated c-Src (Tyr416), c-Src, and GAPDH in NSC-34 cells overexpressing human wild-type or mutant SOD1s treated with various concentrations of dasatinib were measured by western blot. Cells were cultured in serum-free culture medium with doxycycline (Dox, 2 µg/ml), and western blot was performed at 24 h after dasatinib addition.

p27 / p21; 

PubMed: 20145167     


Dasatnib induced cell cycle arrest. Dasatinib induced growth arrest, shown as a cell cycle distribution graph in the lower panel, correlated with increased p27 and p21 levels. Western blotting for levels of p27 and p21 was performed on protein lysates of THP-1 cells treated for 48 hours with indicated doses of dasatinib or DMSO. Detection of actin served as control for comparable protein loading.

p-FAK / p-STAT3; 

PubMed: 23721490     


The effect of dasatinib in cell signalling. Western blot analysis with phosphorylated Src, FAK, Stat3, Akt and MAPK in HCC cell lines after 24 hours treatment of dasatinib. The cell lines were arranged according to their IC50 to dasatinib. The top three were most sensitive, the bottom 3 were least sensitive.

cleaved caspase 3; 

PubMed: 20145167     


Dasatinib induced apoptosis. Dasatinib causes apoptosis in Mo7e-KitD816H cells as detected by cleavage of caspase 3. Whole cell lysates were prepared after 24 hour treatment with dasatinib. Caspase 3 and cleaved capase 3 were analyzed by western blotting. Actin serves as loading control.

23049975 20145167 23721490
Growth inhibition assay
IC50; 

PubMed: 23721490     


9 HCC cell lines were exposed to the dedicated concentrations of dasatinib for 72 hours, and IC50 was tested by MTS. Results represent the mean (± SD) of three experiments.

23721490
Immunofluorescence
SRC / Met; 

PubMed: 26517812     


Immunocytochemistry of SRC and Met localization. Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in A. LN-18 and B. U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively.

F-actin / Actinin-4 / Paxillin; 

PubMed: 31053734     


Conditionally immortalized differentiated podocytes treated for one-hour with 2 µM kinase inhibitor were stained for F-actin (phalloidin), α-actinin-4, paxillin, and nuclei (Hoechst 33342) to assess cytoskeletal and focal adhesion architecture (scale bars = 50 µm). Podocytes treated with dasatinib showed a marked decrease in cell-to-cell contacts, cell size and number of focal adhesions.

α-tubulin; 

PubMed: 26517812     


Combination of dasatinib and crizotinib impedes the formation of the α-tubulin-labeled mitotic spindle. LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm.

26517812 31053734
ELISA
TNF-α; 

PubMed: 17684099     


U937 cells were differentiated with vitamin D3, pretreated with the indicated concentrations of drugs for 1 h and stimulated with LPS for 6 h. TNF-α secretion was measured by ELISA. The graph shows the mean of two experiments done in duplicate.

E-selectin; 

PubMed: 31110200     


HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of E-selectin was determined using ELISA (n = 3, ±SEM).

VCAM-1; 

PubMed: 31110200     


HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of VCAM-1 was determined using ELISA (n = 3, ±SEM).

17684099 31110200
In vivo Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]

Protocol

Kinase Assay:

[1]

- Collapse

Kinase autophosphorylation assays:

Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
Cell Research:

[1]

- Collapse
  • Cell lines: Ba/F3 cell lines
  • Concentrations: ~32 nM
  • Incubation Time: 72 hours
  • Method:

    Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.


    (Only for Reference)
Animal Research:

[3]

- Collapse
  • Animal Models: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
  • Dosages: 30 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 98 mg/mL (200.81 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 488.01
Formula

C22H26ClN7O2S

CAS No. 302962-49-8
Storage powder
in solvent
Synonyms BMS-354825
Smiles CC1=NC(=CC(=N1)N2CCN(CCO)CC2)NC3=NC=C(S3)C(=O)NC4=C(Cl)C=CC=C4C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04063124 Suspended Drug: Dasatinib + Quercetin Alzheimer Disease The University of Texas Health Science Center at San Antonio|Mayo Clinic February 14 2020 Phase 1|Phase 2
NCT04155411 Recruiting Drug: Dasatinib Dasatinib|BCR-ABL|Chronic Myeloid Leukemia Shenzhen Second People''s Hospital December 1 2019 Phase 4
NCT04115059 Recruiting Drug: Dasatinib Waldenstrom Macroglobulinemia|DASATINIB Jorge J. Castillo MD|Bristol-Myers Squibb|Dana-Farber Cancer Institute November 4 2019 Phase 1
NCT03318770 Not yet recruiting Drug: Dasatinib and blinatumomab Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dell''Adulto December 2018 --
NCT03625388 Recruiting Drug: Dasatinib Chronic Myelogenous Leukemia Hikma Pharmaceuticals LLC November 5 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    what’s the difference between S1021 and S7782? Which one is better for in vivo studies?

  • Answer:

    Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).

  • Question 2:

    Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?

  • Answer:

    Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Related Src Products

Tags: buy Dasatinib | Dasatinib supplier | purchase Dasatinib | Dasatinib cost | Dasatinib manufacturer | order Dasatinib | Dasatinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID